Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Global Hemophilia B Market 2015-2019 - Industry Analysis

Published: Sep-2015 | Format: PDF | Technavio | Number of pages: 60 | Code: MRS - 35080

Hemophilia B, also called the Christmas disease, is a blood coagulation disorder due to the deficiency or improper function of factor IX. It is inherited in an X-linked recessive pattern. This disorder is more prevalent in males than in females. Factor replacement therapies, mainly recombinant, are used in the treatment.

The analysts forecast global hemophilia B market to grow posting a CAGR of 4.18% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global hemophilia B market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hemophilia B.

The report, Global Hemophilia B Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and landscape. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Baxter
  • Grifols
  • Novo Nordisk
  • Pfizer

Other prominent vendors

  • Alnylam
  • Amarna
  • Asklepios
  • Biogen
  • Catalyst Biosciences
  • CSL Behring
  • Dimension Therapeutics
  • Dong-A Scio
  • Emergent BioSolutions

Key market driver

  • Prophylactic treatment
  • For a full, detailed list, view our report

Key market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Key market trend

  • New technological advancements
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 06: Disease overview
Understanding the disease

PART 07: Pipeline portfolio
Key information of few pipeline candidates

PART 08: Market segmentation by disease severity
Mild hemophilia B
Moderate hemophilia B
Severe hemophilia B

PART 09: Market segmentation by disease management
On-demand therapy
Prophylactic therapy
Inhibitor therapy

PART 10: Geographical segmentation

PART 11: Market drivers
Focus on prophylactic treatment
Drugs with prolonged action
Patient assistance programs

PART 12: Impact of drivers

PART 13: Market challenges
High cost of therapy
Low diagnosis rate in developing countries
Complications of available therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends
Advances in technology
Strategic alliances
Development of gene therapy products

PART 16: Vendor landscape
Competitive scenario
Mergers and acquisitions
Market share analysis 2014
Other prominent vendors

PART 17: Key vendor analysis
Novo Nordisk

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Global hemophilia B market 2014-2019 ($ billions)
Exhibit 03: Five forces analysis
Exhibit 04: Global cases of hemophilia B 2010-2013
Exhibit 05: Cases of Hemophilia B by region 2012
Exhibit 06: Cases of hemophilia B by region 2013
Exhibit 07: Global hemophilia B market segmentation by disease severity
Exhibit 08: Global hemophilia B market segmentation by disease severity 2014
Exhibit 09: Treatment of severe hemophilia B 2014
Exhibit 10: Global hemophilia B market segmentation by disease management
Exhibit 11: Share of prophylactic therapy by region 2014
Exhibit 12: Types of prophylaxis
Exhibit 13: Global hemophilia B market segmentation by disease management 2014
Exhibit 14: Global hemophilia B market segmentation 2014
Exhibit 15: Global hemophilia B market segmentation by revenue 2014 ($ billions)
Exhibit 16: Impact of drivers
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Baxter: Global sales of hemophilia B drugs 2014-2017 ($ millions)
Exhibit 19: Baxter: Key takeaways
Exhibit 20: Grifols: Key takeaways
Exhibit 21: Novo Nordisk: Global sales of NovoSeven 2011-2014 ($ millions)
Exhibit 22: Novo Nordisk: Key takeaways
Exhibit 23: Pfizer: Global sales of BeneFIX 2011-2014 ($ millions)
Exhibit 24: Pfizer: Key takeaways
Exhibit 25: Novo Nordisk: Business segmentation by revenue 2014
Exhibit 26: Novo Nordisk: Business segmentation by revenue 2013 and 2014
Exhibit 27: Novo Nordisk: Geographical segmentation by revenue 2014
Exhibit 28: Novo Nordisk: R&D expenditure 2014

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2500 View Pricing